Tag Archives: M&A

Pfizer Adds FoldRx to its Specialty Care Unit

By George Koroneos | Published: September 1, 2010
Pfizer on Wednesday announced that it acquired a small rare-disease drug firm, FoldRx, for an undisclosed sum of money. Pfizer spokeswoman Gwen Fischer told Pharm Exec that the deal came together in a matter of weeks, and that FoldRx will be fully incorporated into Pfizer’s research division. All of FoldRx’s employees are expected to become Pfizer [...]
Posted in Deals, Strategy | Also tagged , | Leave a comment

Genzyme Snubs Sanofi Offer

By George Koroneos | Published: August 31, 2010
Less than 24 hours after offering to purchase Genzyme for $18.5 billion, Sanofi-Aventis was sent a letter of rejection from the biotech firm’s board of directors stating that the offer just wasn’t worth it. “Without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your opportunistic [...]
Posted in Deals | Also tagged , | Leave a comment

M&A Round-up • 3/25/2009

By George Koroneos | Published: March 25, 2009
The latest round of merger and acquisition activities courtesy of our friends at Pharm Exec Europe: • Just days after its purchase of Genentech, Roche has made another acquisition, albeit a much smaller one, of the German firm Innovatis. Roche will pay EUR 15 million for the cell analytics company. • Oxford Gene Technology (OGT) is to [...]
Posted in Deals | Also tagged , , , , , , , , , | Leave a comment

Roche and Genentech Seal the Deal
for $46.8 Billion

By George Koroneos | Published: March 12, 2009
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it’s been looking for: Genentech’s board of directors, this morning, approved Roche’s latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. Roche plans to keep the Genentech site in [...]
Posted in Biotech | Also tagged , , , , , | 1 Comment

Conversation with Eisai’s Lonnel Coats

By Joanna Breitstein | Published: November 7, 2008
“The phones are ringing,” said Lonnel Coats, president of Eisai and a plenary speaker here at HBA’s Leadership Conference. “There’s a lot more opportunity, but also a lot more white noise.” Coats is referring to the pressure that cash-strapped biotechs are feeling to sell out and says he gets no less than five calls a day [...]
Posted in Events, Strategy | Also tagged , , , , | Leave a comment